Drugs / Terlipressin
Terlipressin
also known as
Glypressin · Glycylpressin · Terlipresina · Terlipressin acetate · Terlipressine · Terlivaz · triglycyl-lysine vasopressin · Variquel
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TERLIVAZ | — | 2022-09-14 | fda.gov ↗ |
Trials 52 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 35 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05080543 Comparator | Oct 2021 → Sep 2022 | infectious disease with sepsis | Amany Mousa Salama Muhammed | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06256432 Comparator | Apr 2024 → May 2026 overdue | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | Noorik Biopharmaceuticals AG | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04339868 Comparator | Apr 2020 → Mar 2025 | infectious disease with sepsis | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT04110418 Comparator | Feb 2019 → Feb 2020 | neonatal sepsis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03572088 Comparator | May 2016 → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02718599 Comparator | Apr 2016 → Jul 2017 | portal hypertension, noncirrhotic | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02588716 Comparator | Sep 2015 → Mar 2016 | hepatic infarction | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01921985 Comparator | Nov 2013 → Mar 2018 | liver failure | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00742339 Comparator | May 2005 → Oct 2013 | cirrhosis of liver, hepatorenal syndrome | University of Padova | Terminated | No outcome recorded |
| Phase 2/3 | NCT00742690 Comparator | May 2005 → Dec 2014 | cirrhosis of liver, hepatorenal syndrome | University of Padova | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06027970 Comparator | Sep 2023 → Aug 2024 | esophageal varices with bleeding | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT03822091 Comparator | Jan 2019 → Jan 2020 | hepatorenal syndrome | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT01637454 Comparator | Jan 2009 → Dec 2011 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT00370253 Comparator | Sep 2006 → Sep 2007 | hepatorenal syndrome | University of Turin, Italy | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT05806307 Comparator | Mar → Oct 2023 | drug pseudoallergy, uterine corpus leiomyoma | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03584087 Comparator | May 2018 → Jul 2019 | esophageal varices with bleeding | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 4 | NCT02489864 Comparator | Jul 2015 → Jul 2017 | hepatorenal syndrome | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02757703 Comparator | May 2010 → Jan 2015 | esophageal varices with bleeding | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT01112852 Comparator | Dec 2006 → Apr 2010 | esophageal varices, hemorrhagic disease | National Science and Technology Council, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00863837 Comparator | Dec 2006 → Nov 2009 | esophageal varices with bleeding | National Science and Technology Council, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT00966355 Comparator | Sep 2006 → May 2010 | esophageal varices with bleeding | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT00369694 Comparator | Aug 2006 → Jul 2008 | esophageal varices, hemorrhagic disease, portal hypertension | Aga Khan University | Completed | No outcome recorded |
| Phase 4 | NCT00534677 Comparator | May 2004 → Jul 2005 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Aga Khan University | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07304466 Comparator | Dec 2025 → Mar 2027 expected | portal hypertension | Istanbul Medipol University Hospital | Recruiting | No outcome recorded |
| — | NCT05774067 Comparator | Dec 2022 → Jun 2023 | hypotensive disorder | Tanta University | Completed | No outcome recorded |
| — | NCT05346393 Comparator | Nov 2022 → Jun 2025 overdue | acute kidney injury, cirrhosis of liver, hepatorenal syndrome | Jena University Hospital | Recruiting | No outcome recorded |
| — | NCT05154279 Comparator | Feb 2022 → Dec 2024 | uterine corpus leiomyoma | Wael Elbanna Clinic | Unknown | No outcome recorded |
| — | NCT05170230 Comparator | Feb 2022 → Dec 2024 | leiomyoma | Wael Elbanna Clinic | Unknown | No outcome recorded |
| — | NCT05242783 Comparator | Feb 2022 → Mar 2024 | leiomyoma | Wael Elbanna Clinic | Completed | No outcome recorded |
| — | NCT05266534 Comparator | Dec 2021 → Jun 2024 overdue | leiomyoma | Wael Elbanna Clinic | Recruiting | No outcome recorded |
| — | NCT04013113 Background | Jul 2019 → Jul 2020 | liver disorder | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02788240 Background | May 2016 → Jul 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Terminated | No outcome recorded |
| — | NCT02573727 Comparator | Oct 2015 → Jan 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01649037 Comparator | Aug 2012 → Jun 2015 | hepatorenal syndrome | Institute of Liver and Biliary Sciences, India | Withdrawn | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 89 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terlipressin | “nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be...” NCT04013113 ↗85“15 women will receive terlipressin (Glypressin, Ferring, Egypt) intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml” NCT05806307 ↗ “Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.” NCT03608514 ↗ “The standard treatment of HRS-AKI is with the infusion of albumin and terlipressin.” NCT05346393 ↗ “The active substance is terlipressin acetate.” NCT04110418 ↗ |
| Known as | Glycylpressin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2135460 ↗ |
| Known as | Glypressin | “The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg...” NCT05331768 ↗3“Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.” NCT02757703 ↗ “terlipressin (Glypressin®) will be administered as a 1 mg bolus over 2 minutes, followed by a continuous infusion at 2 mcg/kg/hour.” NCT07304466 ↗ |
| Known as | Terlipresina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2135460 ↗ |
| Known as | Terlipressin acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2135460 ↗ |
| Known as | Terlipressine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2135460 ↗ |
| Known as | Terlivaz | “In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg...” NCT05875948 ↗ |
| Known as | triglycyl-lysine vasopressin | “Terlipressin (triglycyl-lysine vasopressin) became popular in the early 1990s because it has a prolonged duration of action.” NCT05154279 ↗ |
| Known as | Variquel | ChEMBL registry synonym — accepted as the source's own label CHEMBL2135460 ↗ |
| Action | Activate | “terlipressin, a V1 vasopressin agonist” NCT00370253 ↗ |
| Modality | Peptide | “Terlipressin, a synthetic vasopressin analogue” PMID 28370090 ↗ Mar 2017 |
| Route | Intravenous | “Patients received intravenous terlipressin 1-2 mg every 6 hours” PMID 28370090 ↗ Mar 2017 |
| Target | AVPR2 | “Vasopressin V2 receptor binding agent” CHEMBL2135460 ↗ |